Kalium phosphoricum 6c homeopathic tablets

Objective This Phase IV placebo-controlled clinical trial was designed to demonstrate efficacy and safety of the product NeurodoronFootnote1 (Kalium phosporicum comp., KPC) in patients with neurasthenia.Methods This monocenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial (registration number: DRKS00003261) was conducted in an outpatient German trial site. Women and men aged 18 and above were randomized to receive either KPC or placebo if they reported typical symptoms of neurasthenia and a severe psychiatric disorder could be excluded. The primary objectives were a reduction in characteristic symptoms of nervous exhaustion and perceived stress as well as improvement in general health status after 6 weeks of treatment.Results 204 patients underwent screening, 78 were randomized in each treatment group, and 77 patients each received treatment (intention-to-treat (ITT) population = 154 patients). For none of the primary efficacy variables, an advantage in favor of KPC could be demonstrated in the pre-specified analysis (p-values between 0.505 to 0.773, Student's t-test). In a post-hoc analysis of intra-individual differences after 6 weeks treatment, a significant advantage of KPC vs. placebo was shown for characteristic symptoms of nervous exhaustion (irritability (p = 0.020); nervousness (p = 0.045), Student's t-test). Adverse event (AE) rates were similar between treatment groups, in both groups 6 AEs were assessed as causally related to treatment (severity mild or moderate). No AE resulted in discontinuation of treatment.Conclusions Trial treatment was well tolerated with only few and minor AEs reported, confirming the markedly good safety of KPC. A significant improvement of neurasthenia was seen for the total study population at the end of the treatment period. Superiority of KPC vs. placebo could not be demonstrated with the pre-specified analysis in regards to a sum score of 12 typical symptoms, perceived stress or general health status. However, the explorative post-hoc analysis revealed that KPC is superior to placebo in the characteristic symptoms irritability and nervousness. KPC could therefore be a beneficial treatment option for symptomatic relief of neurasthenia.

Abstract licence: CC BY-NC-ND 4.0

Background: Chronic insomnia is a prevalent yet underdiagnosed condition affecting quality of life. Conventional treatments have limitations, highlighting the need for safe, individualised approaches. Homoeopathy, emphasising totality-based prescribing, offers an integrative solution, but comparative research on standardised versus individualised homoeopathic interventions is limited. Objectives: The study compares the clinical efficacy of individualised homoeopathic treatment (IHT) and Kalium Phosphoricum in managing chronic insomnia. Methods: A randomised, single-blind clinical trial was conducted on 30 patients diagnosed with chronic insomnia (ICSD-III and DSM-5 criteria) at a homoeopathic medical institution. Participants were randomised into two groups: one receiving Kalium Phosphoricum and the other receiving individualised remedies based on constitutional analysis. Outcomes were assessed using the Insomnia Severity Index (ISI). Results: Both groups showed significant improvement in ISI scores, with the IHT group showing a greater reduction (21.4 points) compared to the Kalium Phosphoricum group (8.67 points). Conclusion: The study found that personalised homoeopathic treatment, which differs from Kalium Phosphoricum, is more effective in managing chronic insomnia, thereby suggesting the potential benefit of individualised prescribing; however, findings are preliminary, limited by a small sample, subjective outcomes, and lack of placebo control.

Abstract licence: CC BY-NC-SA 4.0

Background: Acute infections in children are prevalent and often lead to antibiotic overuse due to the lack of evidence-based alternative approaches. Phytotherapeutic, homeopathic treatments and bee products are frequently sought as alternative or adjunctive therapies. This scoping review aims to map the existing evidence on the efficacy and safety of these interventions in managing acute pediatric infections. Methods: A comprehensive literature search was conducted across multiple databases to identify studies assessing the use of phytotherapeutic, homeopathic remedies and bee products in children with acute infections. Gastrointestinal infections were not considered since the use of non-antibiotic treatments (probiotics) in these conditions has been widely addressed. Effectiveness: Phytotherapeutic agents and bee products demonstrated promising results in reducing symptom severity and duration in respiratory infections, whereas homeopathic data were limited and inconsistent. Regarding safety, both interventions were generally well-tolerated, with few adverse events reported. No studies or very limited evidence were available for other acute infections such as urinary, dermatological, osteoarticular and nervous system infections. Conclusions: Phytotherapeutic interventions and bee products, particularly in acute upper respiratory tract and acute bronchitis, show encouraging signals of efficacy and safety in pediatric populations. However, evidence for their use in other frequent childhood infections, such as otitis media, or gastrointestinal infections, is almost entirely lacking. In addition, the available literature on homeopathic remedies is scarce and methodologically inconsistent, preventing any firm conclusions. Well-designed, large-scale clinical trials focusing on these underexplored conditions are needed to clarify the potential role of phytotherapeutics and homeopathy in pediatric infectious diseases.

Abstract licence: CC BY